About Calviri

About company

Calviri provides cancer treatment products by combining the immunogenic source of neoantigens with a peptide array platform. On its course to eradicate cancer it develops new diagnostic and therapeutic products, and then preventative vaccines that will stop cancer from starting. The company's approach can provide both cancer diagnostics and vaccines. It is based on the discovery of an unrecognized source of frameshift neoantigens. These immunogenic peptides are generated from very frequent errors in tumor-cell RNA synthesis and processing. They provide both cancer-specific and shared frameshift neoantigens for a new class of diagnostic and vaccine products. Calviri was founded in 2018 and is headquartered in Tempe, Arizona.